Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.49 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.49 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.45 |
| ▸ | LGMN | Q99538 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 3/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.44 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.43 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.43 |
| ▸ | EP300 | Q09472 | 1/20 | 0.42 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8666063 | 0.83 | HSD17B10 (0.53) | LMNAPDE3BPDE3AHRH3MAPT | |
| SCHEMBL23759875 | 0.80 | ADRB1 (0.51) | ALDH1A1CYP1A2HTT | |
| SCHEMBL18436001 | 0.79 | ADRA2C (0.47) | MAPKAPK5HRH3MAPTALDH1A1KDM4E | |
| SCHEMBL19264139 | 0.77 | HRH3 (0.53) | LMNAHRH3HTT | |
| SCHEMBL31463645 | 0.77 | ATM (0.45) | PIK3CAPIK3CBPIK3C3PRKDCPDE3B | |
| SCHEMBL28826859 | 0.76 | PIK3CD (0.53) | PIK3CAPIK3CDPIK3CBLMNALGMN | |
| SCHEMBL444108 | 0.75 | GHSR (0.52) | PIK3CAPIK3CDPIK3CBLMNALGMN | |
| SCHEMBL21336580 | 0.75 | HRH3 (0.64) | HRH3MAPTALDH1A1KDM4EPKM | |
| SCHEMBL29778435 | 0.74 | PIK3CD (0.59) | PIK3CAPIK3CDPIK3CBLMNALGMN | |
| SCHEMBL28024737 | 0.74 | PRKDC (0.51) | PIK3CAPIK3CDPIK3CBLRRK2PRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4069366-B1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI FOUNDATION INC (US) | 2025-03-19 | — | — | EP | disclosed |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | Spring Bioscience AB (SE) | 2024-02-15 | — | — | US | disclosed |
| EP-4069366-A1 | ATM KINASE INHIBITORS AND COMPOSITIONS AND METHODS OF USE THEREOF | CHDI Foundation, Inc. (US) | 2022-10-12 | — | — | EP | disclosed |
| US-20220117974-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2022-04-21 | — | — | US | disclosed |
| CN-113845472-A | 6-aryl-4-morpholin-1-ylpyridinone compounds useful for the treatment of cancer and diabetes | 思普瑞特生物科学公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113845472-A | 6-aryl-4-morpholin-1-ylpyridinone compounds useful for the treatment of cancer and diabetes | 思普瑞特生物科学公司 | 2021-12-28 | — | — | CN | disclosed |
| CN-113754581-A | 6-aryl-4-morpholin-1-ylpyridinone compounds useful for the treatment of cancer and diabetes | 思普瑞特生物科学公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-113754581-A | 6-aryl-4-morpholin-1-ylpyridinone compounds useful for the treatment of cancer and diabetes | 思普瑞特生物科学公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-108698996-B | 6-aryl-4-morpholin-1-ylpyridinone compounds useful for the treatment of cancer and diabetes | 思普瑞特生物科学公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-108698996-B | 6-aryl-4-morpholin-1-ylpyridinone compounds useful for the treatment of cancer and diabetes | 思普瑞特生物科学公司 | 2021-10-01 | — | — | CN | disclosed |
| US-11077113-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | SPRINT BIOSCIENCE AB (SE) | 2021-08-03 | — | — | US | disclosed |
| US-20210128571-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2021-05-06 | — | — | US | disclosed |
| EP-3416945-B1 | 6-ARYL-4-(MORPHOLIN-4-YL)-1H-PYRIDIN-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | SPRINT BIOSCIENCE AB (SE) | 2020-07-01 | — | — | EP | disclosed |
| CN-105143209-A | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG | 2015-12-09 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220117974-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | PYCR1, GPR119, IL6 | PIK3CA 2742/4885PIK3CD 3456/4885PIK3CB 3842/4885 |
| US-11077113-B2 | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes | PYCR1, GPR119, IL6 | PIK3CA 2742/4885PIK3CD 3456/4885PIK3CB 3842/4885 |
| US-20210128571-A1 | 6-HETEROCYCLYL-4-MORPHOLIN-4-YLPYRIDINE-2-ONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | GPR119, PYCR1, CDK6 | PIK3CA 2054/4885PIK3CD 2305/4885PIK3CB 2961/4885 |
| US-20240050439-A1 | 6-ARYL-4-MORPHOLIN-1-YLPYRIDONE COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER AND DIABETES | PYCR1, GPR119, CDK6 | PIK3CA 2783/4885PIK3CD 3497/4885PIK3CB 3874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.